Skip to main
APGE

APGE Stock Forecast & Price Target

APGE Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 7%
Hold 60%
Sell 0%
Strong Sell 0%

Bulls say

Apogee Therapeutics is positioned for success due to its strong pipeline of optimized biologics targeting well-established mechanisms of action, its successful de-risking of therapeutic targets through advanced data generation, and its potential for dosing convenience in large revenue opportunities in the I&I market. The company's acquisition by ABBV further validates the interest in long half-life and combination assets in the I&I space. Despite risks related to clinical trial failure or regulatory approval, the successful closing of the deal with ABBV and continued advancements in its pipeline could lead to a significant increase in Apogee's stock value.

Bears say

Apogee Therapeutics is facing challenges with the potential safety issues of their long-acting OX40L antibody and the deprioritization of their IL-4Rα asset. The company has a potential fair value of $135/shr based on a 6x multiple to 2032-35E sales of each clinical-stage candidate in each target addressable indication, discounted back by a risk-adjusted discount rate. Despite having a peak revenue potential of $7B and significant market opportunities in I&I indications, there are concerns surrounding the company's sustainability and adherence to ethical practices.

APGE has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 7% recommend Buy, 60% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apogee Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apogee Therapeutics Inc (APGE) Forecast

Analysts have given APGE a Buy based on their latest research and market trends.

According to 15 analysts, APGE has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $129.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $129.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apogee Therapeutics Inc (APGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.